Interaksi Elvitegravir, kobisistat, emtrisitabin, dan tenofovir dan Hidrokodon dan homatropin

Elvitegravir, kobisistat, emtrisitabin, dan tenofovir dan Hidrokodon dan homatropin: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Hidrokodon dan homatropin (Hydrocodone Bitartrate and Homatropine Methylbromide) · berlaku sejak 2026-05-07

Mayor

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and homatropine methylbromide with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking a CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.7) , Drug Interactions (7.2 , 7.3) ] .

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients taking CYP3A4 inhibitors or inducers.

Peringatan kotak hitamberdasarkan golongan obatLihat label di DailyMed
Mayor

Avoid the use of hydrocodone bitartrate and homatropine methylbromide in patients who are taking a CYP3A4 inhibitor or inducer.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed

Dari label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir (Genvoya) · berlaku sejak 2025-02-03

Mayor

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which…

Kontraindikasiberdasarkan golongan obatLihat label di DailyMed
Moderat

Sedative/hypnotic: midazolam (oral) triazolam ↑ midazolam ↑ triazolam Coadministration with triazolam or orally administered midazolam is contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. buspirone zolpidem With other sedative/hypnotics, dose reduction may be necessary and clinical monitoring is recommended.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Other benzodiazepines: e.g., parenterally administered midazolam clorazepate diazepam estazolam flurazepam ↑ sedatives/hypnotics Triazolam and orally administered midazolam are extensively metabolized by CYP3A.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Tanpa interaksi

Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.